FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2123453386> ?p ?o ?g. }

• W2123453386 endingPage "602" @default.
• W2123453386 startingPage "599" @default.
• W2123453386 abstract "Oligodendroglial tumors are chemosensitive, with two-thirds of patients responding to PCV combination chemotherapy with procarbazine, lomustine (CCNU) and vincristine. Temozolomide (TMZ), a new alkylating and methylating agent has shown high response rates in recurrent anaplastic astrocytoma. We investigated this drug in recurrent oligodendroglial tumors (OD) and mixed oligoastrocytomas (OA) after prior PCV chemotherapy and radiation therapy.In a prospective non-randomized multicenter phase II trial patients were treated with TMZ 150 mg/m(2) on days 1-5 in cycles of 28 days for 12 cycles. Eligible patients had a recurrence after prior PCV chemotherapy, with measurable and enhancing disease as shown by magnetic resonance imaging. Pathology and all responses were centrally reviewed.Thirty-two eligible patients were included. In four patients the pathology review did not confirm the presence of an OD or OA. Twelve of 24 patients [50%, 95% confidence interval (CI) 29% to 71%] evaluable for response to first-line PCV chemotherapy had responded to PCV. Temozolomide was in general well tolerated; the most frequent side-effects were hematological. One patient discontinued treatment due to toxicity. In seven of 28 patients (25%, 95% CI 11% to 45%) with histologically confirmed OD an objective response to TMZ was observed. Median time to progression for responding patients was 8.0 months. After 6 and 12 months from the start of treatment, 29% and 11% of patients, respectively, were still free from progression.TMZ may be regarded as the preferred second-line treatment in OD after failure of PCV chemotherapy. Further studies on TMZ in OD are indicated." @default.
• W2123453386 created "2016-06-24" @default.
• W2123453386 creator A5006238946 @default.
• W2123453386 creator A5010891460 @default.
• W2123453386 creator A5014040254 @default.
• W2123453386 creator A5030490879 @default.
• W2123453386 creator A5041574488 @default.
• W2123453386 creator A5056837393 @default.
• W2123453386 creator A5075152654 @default.
• W2123453386 creator A5075387803 @default.
• W2123453386 creator A5085298662 @default.
• W2123453386 creator A5090644978 @default.
• W2123453386 date "2003-04-01" @default.
• W2123453386 modified "2023-10-16" @default.
• W2123453386 title "Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972" @default.
• W2123453386 cites W1751296883 @default.
• W2123453386 cites W1795588153 @default.
• W2123453386 cites W1913672130 @default.
• W2123453386 cites W195642970 @default.
• W2123453386 cites W1959628099 @default.
• W2123453386 cites W1975916416 @default.
• W2123453386 cites W1997964607 @default.
• W2123453386 cites W2029409133 @default.
• W2123453386 cites W2036447996 @default.
• W2123453386 cites W2046289133 @default.
• W2123453386 cites W2046796218 @default.
• W2123453386 cites W2108912769 @default.
• W2123453386 cites W2113647927 @default.
• W2123453386 cites W2131518655 @default.
• W2123453386 cites W2264385870 @default.
• W2123453386 cites W4293241248 @default.
• W2123453386 doi "https://doi.org/10.1093/annonc/mdg157" @default.
• W2123453386 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12649108" @default.
• W2123453386 hasPublicationYear "2003" @default.
• W2123453386 type Work @default.
• W2123453386 sameAs 2123453386 @default.
• W2123453386 citedByCount "150" @default.
• W2123453386 countsByYear W21234533862012 @default.
• W2123453386 countsByYear W21234533862013 @default.
• W2123453386 countsByYear W21234533862014 @default.
• W2123453386 countsByYear W21234533862015 @default.
• W2123453386 countsByYear W21234533862016 @default.
• W2123453386 countsByYear W21234533862017 @default.
• W2123453386 countsByYear W21234533862018 @default.
• W2123453386 countsByYear W21234533862019 @default.
• W2123453386 countsByYear W21234533862020 @default.
• W2123453386 countsByYear W21234533862021 @default.
• W2123453386 countsByYear W21234533862022 @default.
• W2123453386 countsByYear W21234533862023 @default.
• W2123453386 crossrefType "journal-article" @default.
• W2123453386 hasAuthorship W2123453386A5006238946 @default.
• W2123453386 hasAuthorship W2123453386A5010891460 @default.
• W2123453386 hasAuthorship W2123453386A5014040254 @default.
• W2123453386 hasAuthorship W2123453386A5030490879 @default.
• W2123453386 hasAuthorship W2123453386A5041574488 @default.
• W2123453386 hasAuthorship W2123453386A5056837393 @default.
• W2123453386 hasAuthorship W2123453386A5075152654 @default.
• W2123453386 hasAuthorship W2123453386A5075387803 @default.
• W2123453386 hasAuthorship W2123453386A5085298662 @default.
• W2123453386 hasAuthorship W2123453386A5090644978 @default.
• W2123453386 hasBestOaLocation W21234533861 @default.
• W2123453386 hasConcept C126322002 @default.
• W2123453386 hasConcept C141071460 @default.
• W2123453386 hasConcept C143998085 @default.
• W2123453386 hasConcept C2776694085 @default.
• W2123453386 hasConcept C2776755627 @default.
• W2123453386 hasConcept C2777389519 @default.
• W2123453386 hasConcept C2777931997 @default.
• W2123453386 hasConcept C2778227246 @default.
• W2123453386 hasConcept C2778336483 @default.
• W2123453386 hasConcept C2778880634 @default.
• W2123453386 hasConcept C2779083369 @default.
• W2123453386 hasConcept C2779112685 @default.
• W2123453386 hasConcept C2779429289 @default.
• W2123453386 hasConcept C2779434656 @default.
• W2123453386 hasConcept C2780739268 @default.
• W2123453386 hasConcept C2780964509 @default.
• W2123453386 hasConcept C2910969760 @default.
• W2123453386 hasConcept C31760486 @default.
• W2123453386 hasConcept C502942594 @default.
• W2123453386 hasConcept C71924100 @default.
• W2123453386 hasConceptScore W2123453386C126322002 @default.
• W2123453386 hasConceptScore W2123453386C141071460 @default.
• W2123453386 hasConceptScore W2123453386C143998085 @default.
• W2123453386 hasConceptScore W2123453386C2776694085 @default.
• W2123453386 hasConceptScore W2123453386C2776755627 @default.
• W2123453386 hasConceptScore W2123453386C2777389519 @default.
• W2123453386 hasConceptScore W2123453386C2777931997 @default.
• W2123453386 hasConceptScore W2123453386C2778227246 @default.
• W2123453386 hasConceptScore W2123453386C2778336483 @default.
• W2123453386 hasConceptScore W2123453386C2778880634 @default.
• W2123453386 hasConceptScore W2123453386C2779083369 @default.
• W2123453386 hasConceptScore W2123453386C2779112685 @default.
• W2123453386 hasConceptScore W2123453386C2779429289 @default.
• W2123453386 hasConceptScore W2123453386C2779434656 @default.
• W2123453386 hasConceptScore W2123453386C2780739268 @default.
• W2123453386 hasConceptScore W2123453386C2780964509 @default.
• W2123453386 hasConceptScore W2123453386C2910969760 @default.

• next